A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 2 – studying effectiveness and dosage
Conditions:
Crohn's Disease
Sponsor: Janssen Research & Development, LLC
trial.available_in:
БГ
Overview
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Who can participate
Inclusion Criteria:
* Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline
* Confirmed diagnosis of moderate to severe CD as assessed by Crohn'
Locations
32
Australia (1)
The Queen Elizabeth Hospital
Adelaide
Belgium (1)
GZA Ziekenhuizen
Antwerp
Brazil (1)
Hospital Das Clinicas Da Ufmg
Belo Horizonte - MG
Bulgaria (1)
UMHAT 'Aleksandrovska' EAD
Sofia
Canada (1)
Foothills Hospital
Calgary , Alberta
China (1)
China Japan Friendship Hospital
Beijing
Croatia (1)
Opca bolnica Bjelovar
Bjelovar
Czech Republic (1)
Vojenska nemocnice Brno
Brno
Denmark (1)
Aarhus University Hospital
Aarhus
Estonia (1)
West Tallinn Central Hospital
Tallinn
France (1)
CHU Amiens - Hopital Sud
Amiens
Greece (1)
General Hospital of Athens 'Ippokrateion'
Athens
Hungary (1)
Obudai Egeszsegugyi Centrum Kft
Budapest
India (1)
ICON Hospital Orchid Medi services and Research Private Limited
Ahmedabad
Israel (1)
Haemek Medical Center - Afula
Afula
Italy (1)
Università degli Studi di Bari
Bari
Japan (1)
Asahikawa Medical University Hospital
Asahikawa
Jordan (1)
Jordan University Hospital
Amman
Malaysia (1)
Hospital Sultanah Bahiyah
Alor Star
Netherlands (1)
Academisch Medisch Centrum Universiteit van Amsterdam
Amsterdam
New Zealand (1)
Dunedin Hospital
Dunedin
Norway (1)
Alesund sjukehus
Ålesund
Poland (1)
Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
БГ